July 22 2021: “Sanofi has concluded an agreement to divest an integrated portfolio of dental care brands and related medical devices to Septodont, a French privately-owned company headquartered near Paris.
Divested portfolio includes four dental care brands Ultracain®, Rodogyl®, Birodogyl® and Dontisolon®, as well as related medical devices, mostly marketed in Europe.
This portfolio of high-quality medicines benefits patients both during and after dental operations, while covering most dental indications (anesthetics, anti-infective and anti-inflammatory).
This transaction continues Sanofi’s ongoing strategic transformation announced in December 2019.
The agreement covers the registrations, trademarks, and related commercial rights. This is an asset deal. No employees, equipment or real estate is included.
Commercial terms of the agreement will not be disclosed.
About Septodont
Septodont is a leading manufacturer of dental pharmaceuticals and medical devices.
Since its inception in 1932, the group develops, produces and distributes a large range of products and solutions dedicated to serving the needs of dental professionals across the world.
The group counts 1,900 employees and has a long-established presence in more than 150 countries.
Beyond dental and through its Novocol Pharma division, the group also partners with pharmaceutical and medical device companies to provide contract manufacturing services for pharmaceutical products that require cartridge filling.
Learn more about Septodont’s innovative, safe and healthcare solutions at https://www.septodontcorp.com/.”
https://www.sanofi.com/en/media-room/press-releases/2021/2021-07-22-14-00-00-2267219
